GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Frazier Lifesciences Acquisition Corp (NAS:FLAC) » Definitions » Debt-to-EBITDA

Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Debt-to-EBITDA : 0.00 (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Frazier Lifesciences Acquisition Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Frazier Lifesciences Acquisition's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.00 Mil. Frazier Lifesciences Acquisition's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.00 Mil. Frazier Lifesciences Acquisition's annualized EBITDA for the quarter that ended in Sep. 2022 was $-9.18 Mil. Frazier Lifesciences Acquisition's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Frazier Lifesciences Acquisition's Debt-to-EBITDA or its related term are showing as below:

FLAC's Debt-to-EBITDA is not ranked *
in the Diversified Financial Services industry.
Industry Median: 3.96
* Ranked among companies with meaningful Debt-to-EBITDA only.

Frazier Lifesciences Acquisition Debt-to-EBITDA Historical Data

The historical data trend for Frazier Lifesciences Acquisition's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frazier Lifesciences Acquisition Debt-to-EBITDA Chart

Frazier Lifesciences Acquisition Annual Data
Trend Dec20 Dec21
Debt-to-EBITDA
N/A -

Frazier Lifesciences Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Frazier Lifesciences Acquisition's Debt-to-EBITDA

For the Shell Companies subindustry, Frazier Lifesciences Acquisition's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Frazier Lifesciences Acquisition's Debt-to-EBITDA Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Frazier Lifesciences Acquisition's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Frazier Lifesciences Acquisition's Debt-to-EBITDA falls into.


Frazier Lifesciences Acquisition Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Frazier Lifesciences Acquisition's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -1.366
=0.00

Frazier Lifesciences Acquisition's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -9.176
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2022) EBITDA data.

Frazier Lifesciences Acquisition  (NAS:FLAC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Frazier Lifesciences Acquisition Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Frazier Lifesciences Acquisition's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Frazier Lifesciences Acquisition Corp (NAS:FLAC) » Definitions » Debt-to-EBITDA
Comparable Companies
OMEG LJAQ GSQB PRBM MURF ITAQ APCA JATT SGII MEPW GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
601 Union Street, Two Union Square, Suite 3200, Seattle, WA, USA, 9810
Website
https://www.frazierlifesciencesacquisition.com
Frazier Lifesciences Acquisition Corp is a blank check company.
Executives
David Joseph Topper director, officer: Chief Financial Officer C/O GENERAL ATLANTIC SERVICE COMPANY, LP, 55 EAST 52ND STREET, 32ND FLOOR, NEW YORK NY 10055
Krishna R Polu director C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Robert Jr. Baltera director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830